Patents by Inventor Jian Ge

Jian Ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11197850
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: December 14, 2021
    Assignees: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd.
    Inventors: Jian Ge, Yunfei Li, Lihong Lin, Dengxue Sun, Jiamiao Wang, Yijin Wang, Zhiyun Wang
  • Publication number: 20210332443
    Abstract: A molecular marker for the selection and breeding of fine-wool sheep is disclosed. The marker is an STR marker comprising a (CA)n repeat core sequence, with n between 5 and 24 that can be obtained by PCR amplification of genomic DNA of sheep using the primers shown in SEQ ID NO: 1 and SEQ ID NO: 2 and sequencing the PCR product. When n is 17 or 18, a sheep is a fine-wool breed, and when n is 23 or 24, a sheep is a non-fine-wool breed. When the CA repeat is discontinuous, i.e., divided into two segments (e.g., 12+11 or 13+11) separated by two bases TA or GA, a sheep is a hybrid breed of fine-wool sheep and non-fine-wool sheep. Use of the marker provides methods of identifying of fine-wool sheep breeds, and efficient and accurate selection of fine-wool sheep or the hybrid offspring of fine-wool sheep for breeding.
    Type: Application
    Filed: September 2, 2020
    Publication date: October 28, 2021
    Applicant: China Jiliang University
    Inventors: Feng Guan, Xinyu Hu, Nan Wang, Yuting Jin, Guoqing Shi, Pengcheng Wan, Rong Dai, Aichun Xu, Jian Ge, Jun Liu
  • Publication number: 20210242792
    Abstract: A bipolar bidirectional DC converter comprises at least two valve group series (101, 102) and at least six magnetic elements (103), and said valve group series are divided into a Type-I valve group series (102) and a Type-II valve group series (101) each valve group series (101, 102) comprises a high-voltage DC port, a low-voltage DC port and at least three AC ports, and each AC port is connected to a magnetic element (103); and the other ends of the magnetic elements (103), which are connected to all the AC ports in the same valve group series (101, 102), are connected.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 5, 2021
    Inventors: Chen XIE, Zhongfeng ZHANG, Jie TIAN, Yeyuan XIE, Haiying LI, Yu WANG, Jian GE
  • Patent number: 11072601
    Abstract: Disclosed are a class of ?-opioid receptor agonists and a preparation method therefor and the use thereof in the field of medicine, belonging to the field of medicinal chemistry. The ?-opioid receptor agonists significantly increase the selectivity for a G protein signaling pathway, and not only can exhibit excellent pharmacodynamic effects, but also significantly improve safety.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 27, 2021
    Assignees: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD., ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Xu, Zhen Zhang, Yunfei Li, Liming Zhang, Fengying Guo, Qingyun Jiang, Dongsheng Li, Linli Zhang, Jinqian Song, Lei Liu, Qiang Liu, Jing Su, Yijin Wang, Jian Ge
  • Patent number: 10793536
    Abstract: The present application provides a vortioxetine pamoic acid salt, which includes a crystal form, a solvate or an amorphous substance of the vortioxetine pamoic acid salt. The present application provides a preparation method and use of the vortioxetine pamoic acid salt and the crystal form thereof. The vortioxetine pamoic acid salt prepared in the present application prolongs the residence time of the vortioxetine in vivo, achieving a slow release of the vortioxetine in vivo, and is suitable for preparing a long-acting dosage form.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: October 6, 2020
    Assignee: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD
    Inventors: Yunfei Li, Xiaoer Xia, Xin Xu, Zhen Zhang, Lei Liu, Xiaojuan Zhang, Liming Zhang, Dongsheng Li, Yijin Wang, Jian Ge
  • Publication number: 20200270230
    Abstract: Disclosed are a class of ?-opioid receptor agonists and a preparation method therefor and the use thereof in the field of medicine, belonging to the field of medicinal chemistry. The ?-opioid receptor agonists significantly increase the selectivity for a G protein signaling pathway, and not only can exhibit excellent pharmacodynamic effects, but also significantly improve safety.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 27, 2020
    Inventors: Xin Xu, Zhen Zhang, Yunfei Li, Liming Zhang, Fengying Guo, Qingyun Jiang, Dongsheng Li, Linli Zhang, Jinqian Song, Lei Liu, Qiang Liu, Jing Su, Yijin Wang, Jian Ge
  • Publication number: 20200239842
    Abstract: Preparation and expansion methods for human pluripotent stem cell-derived human retinal pigment epithelial cells are provided. The preparation method includes the following steps: collecting 3D-PRE spheroids derived from human pluripotent stem cells, performing mechanical separation to remove non-RPE cells and clusters which are non-pigmented and retain a pigmented RPE cell sheet, enzymatically digesting the pigmented RPE cell sheet to obtain an RPE single cell suspension, and thereby the human pluripotent stem cell-derived human retinal pigment epithelial cells are obtained. The expansion method includes centrifuging the RPE single cell suspension and removing a supernatant, resuspending in an RPE cell medium and seeding into a cell culture container precoated with extracellular matrix to allow primary culture, and subculturing the cells after cells spread out.
    Type: Application
    Filed: April 28, 2018
    Publication date: July 30, 2020
    Applicant: ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY
    Inventors: Xiufeng ZHONG, Jian GE, Shengxu LIU, Fuhua PENG
  • Publication number: 20200108055
    Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.
    Type: Application
    Filed: February 13, 2018
    Publication date: April 9, 2020
    Inventors: Jian GE, Yunfei LI, Lihong LIN, Dengxue SUN, Jiamiao WANG, Yijin WANG, Zhiyun WANG
  • Patent number: 10456405
    Abstract: Provided are a compound of the formula below, and a pharmaceutically acceptable salt or stereoisomer thereof that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds, a pharmaceutically acceptable salt or stereoisomer thereof and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 29, 2019
    Assignees: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD, SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD
    Inventors: Jian Ge, Yunfei Li, Zhen Zhang, Yijin Wang, Jiamiao Wang, Tao Cheng
  • Patent number: 10375815
    Abstract: The invention discloses a method for adjusting particle orbit alignment by using a first harmonic in a cyclotron, including the following steps: generating a correcting magnetic field through eight coils symmetrically about the middle plane; arranging the positions of the coils and the currents applied, so that they can generate a first harmonic of which the amplitude and phase are arbitrarily adjustable; according to the actual eccentricity of the particle orbit, adjusting the magnitude and direction of the currents applied to the coils, and optimizing the alignment of the particle trajectory. By controlling an external DC power source of the accelerator and combining the real-time feedback of the beam detection of the accelerator, the invention may perform real-time adjustment during the debugging and operation of the accelerator, with high feasibility and operability; compared with traditional methods, the invention may achieve real-time adjustment during the debugging and operation of the accelerator.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: August 6, 2019
    Assignee: HEFEI CAS ION MEDICAL AND TECHNICAL DEVICES CO., LTD.
    Inventors: Yuntao Song, Kaizhong Ding, Jian Ge, Kai Zhou, Yonghua Chen, Junjun Li, Hansheng Feng, Kun Pei, Jian Zhou, Zhong Wang, Xinyu Chen
  • Publication number: 20190169147
    Abstract: The present application provides a vortioxetine pamoic acid salt, which includes a crystal form, a solvate or an amorphous substance of the vortioxetine pamoic acid salt. The present application provides a preparation method and use of the vortioxetine pamoic acid salt and the crystal form thereof. The vortioxetine pamoic acid salt prepared in the present application prolongs the residence time of the vortioxetine in vivo, achieving a slow release of the vortioxetine in vivo, and is suitable for preparing a long-acting dosage form.
    Type: Application
    Filed: March 28, 2017
    Publication date: June 6, 2019
    Inventors: Yunfei LI, Xiaoer XIA, Xin XU, Zhen ZHANG, Lei LIU, Xiaojuan ZHANG, Liming ZHANG, Dongsheng LI, Yijin WANG, Jian GE
  • Publication number: 20190166681
    Abstract: The invention discloses a method for adjusting particle orbit alignment by using a first harmonic in a cyclotron, including the following steps: generating a correcting magnetic field through eight coils symmetrically about the middle plane; arranging the positions of the coils and the currents applied, so that they can generate a first harmonic of which the amplitude and phase are arbitrarily adjustable; according to the actual eccentricity of the particle orbit, adjusting the magnitude and direction of the currents applied to the coils, and optimizing the alignment of the particle trajectory. By controlling an external DC power source of the accelerator and combining the real-time feedback of the beam detection of the accelerator, the invention may perform real-time adjustment during the debugging and operation of the accelerator, with high feasibility and operability; compared with traditional methods, the invention may achieve real-time adjustment during the debugging and operation of the accelerator.
    Type: Application
    Filed: December 3, 2018
    Publication date: May 30, 2019
    Inventors: Yuntao SONG, Kaizhong DING, Jian GE, Kai ZHOU, Yonghua CHEN, Junjun LI, Hansheng FENG, Kun PEI, Jian ZHOU, Zhong WANG, Xinyu CHEN
  • Publication number: 20180250305
    Abstract: Provided are a type of compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
    Type: Application
    Filed: September 6, 2016
    Publication date: September 6, 2018
    Applicants: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD., SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD
    Inventors: Jian GE, Yunfei LI, Zhen ZHANG, Yijin WANG, Jiamiao WANG, Tao CHENG
  • Patent number: 9708306
    Abstract: The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include Ligustrazine and NO donor derivatives. The kind of the compounds can rapidly release Ligustrazine or No in vivo, so that they can produce effective synergetic effects with Azilsartan, to enhance the anti-hypertension effect, and reduce adverse effects, and the released Ligustrazine can produce ideal protection to patients' livers and kidneys, thereby filling blanks in the prior art.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: July 18, 2017
    Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD, WUHAN QR PHARMACEUTICALS CO., LTD
    Inventors: Jian Ge, Jianyi Ma, Guangya Xiang, Wei Wang, Chaodong Wang
  • Patent number: 9696138
    Abstract: A scanning monochromatic spatial low-coherent interferometer (S-LCI) can be used to simultaneously measure geometric thickness and refractive index. The probe beam of the scanning S-LCI can be an off-axis converging single wavelength laser beam, and the decomposed incident angles of the beam on the sample can be accurately defined in the Fourier domain. The angle dependent phase shift of a plane parallel plate or other sample can be obtained in a single system measurement. From the angle dependent phase shift, the geometric thickness and refractive index of the sample can be simultaneously obtained. Additionally or alternatively, the S-LCI system can interrogate the sample to profile the location and refractive index of one or more layers within the sample using the disclosed techniques.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: July 4, 2017
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Xiaoke Wan, Jian Ge
  • Publication number: 20170022188
    Abstract: The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include Ligustrazine and NO donor derivatives.
    Type: Application
    Filed: March 18, 2015
    Publication date: January 26, 2017
    Inventors: Jian GE, Jianyi MA, Guangya XIANG, Wei WANG, Chaodong WANG
  • Publication number: 20140168637
    Abstract: A scanning monochromatic spatial low-coherent interferometer (S-LCI) can be used to simultaneously measure geometric thickness and refractive index. The probe beam of the scanning S-LCI can be an off-axis converging single wavelength laser beam, and the decomposed incident angles of the beam on the sample can be accurately defined in the Fourier domain. The angle dependent phase shift of a plane parallel plate or other sample can be obtained in a single system measurement. From the angle dependent phase shift, the geometric thickness and refractive index of the sample can be simultaneously obtained. Additionally or alternatively, the S-LCI system can interrogate the sample to profile the location and refractive index of one or more layers within the sample using the disclosed techniques.
    Type: Application
    Filed: July 31, 2012
    Publication date: June 19, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Xiaoke Wan, Jian Ge
  • Patent number: 8659845
    Abstract: High-precision monolithic optical assemblies are formed using low-cost standard optical components, such as wedge plates and/or wedge second surface mirrors. By rolling and/or shifting the components relative to each other with matched optical surfaces in contact, a precise alignment solution is found for a particular optical assembly. The resulting arrangement of components can be bonded or held together so as to form a high-precision monolithic optical assembly, which can be inserted into an optical system, according to the assembly's function. The functionality of the monolithic optical assembly can be independent of the optical system in which it is used.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: February 25, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Xiaoke Wan, Jian Ge
  • Patent number: 8570524
    Abstract: Calibration of an arbitrary spectrometer can use a stable monolithic interferometer as a wavelength calibration standard. Light from a polychromatic light source is input to the monolithic interferometer where it undergoes interference based on the optical path difference (OPD) of the interferometer. The resulting wavelength-modulated output beam is analyzed by a reference spectrometer to generate reference data. The output beam from the interferometer can be provided to an arbitrary spectral instrument. Wavelength calibration of the arbitrary spectral instrument may then be performed based on a comparison of the spectral instrument output with the reference data. By appropriate choice of materials for the monolithic interferometer, a highly stable structure can be fabricated that has a wide field and/or is thermally compensated. Because the interferometer is stable, the one-time generated reference data can be used over an extended period of time without re-characterization.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: October 29, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Xiaoke Wan, Jian Ge
  • Publication number: 20130059378
    Abstract: The invention discloses a cell culture medium, human epidermis-derived mesenchymal stem cell-like pluripotent cells and a preparation method thereof. The culture medium is formed by adding fetal bovine serum, hbFGF, hSCF, non-essential amino acids, L-glutamine and gentamicin into a DMEM culture medium with the glucose content of 0.5-5 g/L, wherein every 100 mL of the final culture medium contains 10-25% by volume percent of fetal bovine serum, 100-4000 ng of the hbFGF, 10-2000 ng of hSCF, 0.1-2 mL of 100× non-essential amino acids, 0.1-2 mL of PBS solution containing 3% by mass percent of L-glutamine and 1000-8000 U of gentamicin. A human epidermis-derived mesenchymal stem cell-like pluripotent cell strain is prepared by culturing human epidermal cells in the culture medium, digesting with digestive juice, removing undigested human epidermal cells, collecting digested mesenchymal stem cell-like cells and performing in-vitro culture and passage.
    Type: Application
    Filed: October 16, 2010
    Publication date: March 7, 2013
    Inventors: Bing Huang, Jian Ge